This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Wang JY , Xiu J , Baca Y , Arai H , Battaglin F , Kawanishi N , Soni S , Zhang W , Millstein J , Shields AF , Grothey A , Weinberg BA , Marshall JL , Lou E , Khushman M , Sohal DPS , Hall MJ , Oberley M , Spetzler D , Shen L , Korn WM , Lenz HJ
Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy
Ann Oncol. 2021 Jul;32(7) :906-916
PMID: 33798656 URL: https://www.ncbi.nlm.nih.gov/pubmed/33798656
AbstractPURPOSE: The impact of molecular alterations on PD-L1 combined positive score (CPS) is not well studied in gastroesophageal adenocarcinomas (GEAs). We aimed to characterize genomic features of tumors with different CPSs in GEAs. PATIENTS AND METHODS: Genomic alterations of 2,518 GEAs were compared in three groups (PD-L1 CPS≥10, high; CPS=1-9, intermediate; CPS<1, low) using next-generation sequencing. We assessed the impact of gene mutations on the efficacy of immune checkpoint inhibitors (ICIs) and tumor immune environment based on MSKCC and TCGA databases. RESULTS: CPS-high, intermediate, and low were seen in 18%, 54% and 28% of GEAs respectively. PD-L1 positivity was less prevalent in women and in tissues derived from metastatic sites. PD-L1 CPS was positively associated with dMMR/MSI-H, but independent of TMB distribution. Tumors with mutations in KRAS, TP53 and RAS-MAPK pathway were associated with higher PD-L1 CPSs in the pMMR&MSS subgroup. Patients with RAS-MAPK pathway alterations had longer overall survival (OS) from ICIs compared to wildtype patients [27 vs. 13 months, hazard ratio (HR)=0.36, 95% confidence interval (CI): 0.19-0.7, p=0.016] and a similar trend was observed in the MSS subgroup (p=0.11). In contrast, patients with TP53 mutations had worse OS from ICIs compared to TP53-wildtype patients in the MSS subgroup (5 vs. 21 months, HR=2.39, 95%CI: 1.24-4.61, p=0.016). CONCLUSION: This is the largest study to investigate the distinct genomic landscapes of GEAs with different PD-L1 CPSs. Our data may provide novel insights for patient selection using mutations in TP53 and RAS-MAPK pathway and the development of rational combination immunotherapies in GEAs.
Notes1569-8041 Wang, J Xiu, J Baca, Y Arai, H Battaglin, F Kawanishi, N Soni, S Zhang, W Millstein, J Shields, A F Grothey, A Weinberg, B A Marshall, J L Lou, E Khushman, M Sohal, D P S Hall, M J Oberley, M Spetzler, D Shen, L Korn, W M Lenz, H J Journal Article England Ann Oncol. 2021 Mar 30:S0923-7534(21)01100-5. doi: 10.1016/j.annonc.2021.03.203.